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Dynamics of Plasma Lipidome in 
Progression to Islet Autoimmunity 
and Type 1 Diabetes – Type 1 
Diabetes Prediction and Prevention 
Study (DIPP)
Santosh Lamichhane  1, Linda Ahonen  2, Thomas Sparholt Dyrlund2, Esko Kemppainen1, 
Heli Siljander3,4, Heikki Hyöty5,6, Jorma Ilonen7,8, Jorma Toppari9,10, Riitta Veijola11,12,13, 
Tuulia Hyötyläinen14, Mikael Knip  3,4,15,16 & Matej Oresic1,17
Type 1 diabetes (T1D) is one of the most prevalent autoimmune diseases among children in Western 
countries. Earlier metabolomics studies suggest that T1D is preceded by dysregulation of lipid 
metabolism. Here we used a lipidomics approach to analyze molecular lipids in a prospective series of 
428 plasma samples from 40 children who progressed to T1D (PT1D), 40 children who developed at least 
a single islet autoantibody but did not progress to T1D during the follow-up (P1Ab) and 40 matched 
controls (CTR). Sphingomyelins were found to be persistently downregulated in PT1D when compared 
to the P1Ab and CTR groups. Triacylglycerols and phosphatidylcholines were mainly downregulated in 
PT1D as compared to P1Ab at the age of 3 months. Our study suggests that distinct lipidomic signatures 
characterize children who progressed to islet autoimmunity or overt T1D, which may be helpful in the 
identification of at-risk children before the initiation of autoimmunity.
Type 1 diabetes mellitus (T1D) is a heterogeneous, chronic autoimmune disorder characterized by selective loss 
of the insulin-producing pancreatic beta cells1. Over the past decades, the incidence and prevalence of T1D has 
notably increased among the children in Western countries2 and the number of cases is projected to double 
between 2005 and 2020 among European children3. However, no preventive strategies exist and the underlying 
pathogenesis of T1D is poorly understood.
Human leukocyte antigen (HLA)-conferred genetic susceptibility remains by far the strongest genetic risk 
factor for the disease4, yet less than 10% of the individuals with the high-risk HLA class II genotype progress to 
T1D5. This suggests that extrinsic factors probably contribute to disease development and progression either by 
triggering the immune response or by modifying the destructive process of beta cells in genetically predisposed 
individuals. Substantial evidence suggests that the first signs of beta cell autoimmunity may be initiated during 
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the first year of life6 and a large body of literature1,2,5,7 indicates that environmental factors and gut microbes play 
an important role in the disease development.
Determination of islet autoantibodies is the best known approach for identifying individuals at markedly 
increased risk for developing T1D before the onset of clinical symptoms8. Approximately 15% of children who 
progress to a single autoantibody develop T1D later in life, while for those who progress to multiple autoantibod-
ies the risk is substantially higher (84% after-follow-up for 15 years)9. Earlier metabolomics studies also imply 
that children who progress to T1D are characterized by a specific metabolic profile which can be detected already 
prior to the appearance of islet autoantibodies10–12, suggesting that there is a link between the immune system, 
host metabolism and the development of T1D. However, the information whether the observed lipid-related 
changes are specifically associated with progression to T1D or with islet autoimmunity per se is still scarce. Here 
we analyzed plasma lipidome in a prospective series of samples which included children who progressed to overt 
T1D and control children who did not develop T1D or islet autoantibodies. We also included children who pro-
gressed to sero-positivity for at least a single islet autoantibody but did not progress to T1D during the follow-up, 
i.e., the at-risk children who will most likely not develop T1D9.
Results
Age related changes in the lipidome. We analyzed plasma lipidomics prospectively in three study 
groups: 40 progressors to T1D (PT1D), 40 who progressed to at least a single Ab but not to T1D during the fol-
low-up (P1Ab), and 40 controls (CTR) subjects who remained islet autoantibody negative during the follow-up 
until the age of 15. For each child, up to six time points were included in the analysis, corresponding to the ages 
of 3, 6, 12, 18, 24 or 36 months (Fig. 1). None of the children were diagnosed with T1D at the time of sample 
withdrawal. The lipidomics dataset (n = 428) used for the analysis included identified lipids from the following 
lipid classes: cholesterol esters (CE), diacylglycerols (DG), lysophosphatidylcholines (LPC), phosphatidylcholines 
(PC), phosphatidylethanolamines (PE), sphingomyelins (SM) and triacylglycerols (TG).
Principal Components Analysis (PCA)13 of the preprocessed lipidomics data revealed a clear age-related 
trend. In order to specifically determine the age-related associations in the plasma lipidome, analysis of variance 
(ANOVA)-simultaneous component analysis (ASCA)14 was performed with factors age, gender and case status 
(PT1D, P1Ab, CTR) including their interactions separating the variation into contributions from the different 
factors. Age had the strongest effect (6.01, p = 0.0010) on the plasma lipidomic profile when compared to the 
case group (0.89, p = 0.0050) and gender (0.60, p = 0.0020). However, the interactions between these factors 
remained insignificant. The score plot in Fig. 2a highlights the age-related trend and the corresponding loadings 
plot (Fig. 2b) explains the class-specific lipid alteration related to age. Specifically, the loadings depicts that the 
levels of SMs and LPCs were elevated at the early time points (3, 6, 12 months) while CEs and PEs appeared to 
be higher at later time points (18, 24, 36 months). In contrast, the levels of TGs and PCs varied over time with no 
clear age-related patterns.
Figure 1. An overview of the study setting. The plasma samples for lipidomic analysis were obtained from the 
Finnish Type 1 Diabetes Prevention and Prediction Study (DIPP). The study cohort comprises the samples from 
three groups: children who progressed to T1D during the follow-up (PT1D), who developed at least a single 
islet autoantibody but did not progress to T1D during the follow-up (P1Ab), and control (CTR) subjects who 
remained islet autoantibody negative during the follow-up until the age of 15 years. The three study groups 
were matched by HLA-associated diabetes risk, gender and period of birth. For each child, longitudinal samples 
were obtained corresponding to the ages of 3, 6, 12, 18, 24, and 36 months. These age groups were selected with 
the objective of understanding the dynamics of the lipidome preceding the overt T1D. For each age cohort and 
study group, number of autoantibody positive children is marked.
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Plasma lipidome in development of autoimmunity and progression to T1D. In order to minimize 
the confounding effect of age, data were analyzed separately in different age cohorts. Partial least squares discri-
minant analysis (PLS-DA)15 was performed to examine the differences between the three sample groups using 
combinations of various categorical variables (e.g., PT1D vs. P1Ab, PT1D vs. CTR) in each age cohort.
Figure 3 shows the VIP (variable importance for projection) vs. regression coefficient plot as obtained from 
the PLS-DA analysis, between PT1D (n = 15) and CTR (n = 18) at 3 months of age (AUROC = 0.78). The result 
show lower levels of SMs and higher levels of some PCs in children who later progressed to T1D as compared to 
CTR. Among the PCs, particularly those with a higher number of double bonds (>1) showed an increase in PT1D 
as compared to CTR (Supplementary Fig. 1). In addition, CE (20:4) and PE (36:4) appeared to be higher in PT1D, 
but no clear patterns were seen for the TGs and LPCs. For example, LPC (16:1) was elevated while LPC (16:0e) 
was downregulated in PT1D. Based on the VIP scores, SM (d36:2), SM (d36:1), SM (d34:1), SM (d38:2) and PC 
(40:4), PC (O-34:2), PC (34:2) and PC (O-36:2) were top ranked discriminating lipids in the supervised analysis. 
Univariate analysis showed that at the age of 3 months, a total of 12 lipids were altered between PT1D and CTR 
according to the nominal p-value < 0.05. These lipids included four PCs, seven SMs and one TG (Supplementary 
Table 1). However, none of these lipids passed significance at the selected false discovery rate (FDR) threshold 
of 0.1. The adjusted p-values for SM (d36:1), SM (d34:1), and SM (d36:2) were 0.15, 0.15, and 0.20, respectively.
Figure 2. Principal component analysis (PCA) score plots and loadings based on ANOVA-simultaneous 
component analysis (ASCA). (a) Principal component (PC1) score plot obtained based on age score in ASCA 
analysis. This figure represent the lipidomics dataset arranged according to age in the PCA score plot. Here each 
sample is represented by a point and colored according to the age (red diamond: 3 month of age, green square: 
6 month of age, cyan triangle down: 12 months of age, light yellow circle: 18 months, blue square: 24 months, 
grey white circle 36 months). These ages of the participants are also marked on the x-axis while y-axis represents 
the sample score. Samples with similar score are clustered together. (b) The corresponding PC1 loading plot. 
The loadings explain the pattern seen in the score plot which provides the means to interpret the class specific 
lipid alteration related to age. X-axis is the variable order (i.e. lipids) and y-axis represents the lipids pattern 
corresponding to the score plot. Each color in the loadings represents a lipid class: cholesterol ester (CE), 
diacylglycerol (DG), lysophosphatidylcholine (LPC), phosphatidylcholine (PC), phosphatidylethanolamine 
(PE), sphingomyelin (SM) and triacylglycerol (TG). The loading depicts that the levels of SMs (green circle’s) 
and LPCs (light blue circle’s) were elevated at early time points (3, 6, 12 months) while CEs and PEs appeared to 
be higher in later time point (18, 24, 36 months).
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PLS-DA analysis comparing PT1D (n = 15) and P1Ab (n = 18) at the age of 3 months revealed higher levels of 
SMs and TGs in the P1Ab group (AUROC = 0.67; Supplementary Fig. 2a). Univariate analysis showed that a total 
of 45 lipids being different between PT1D and P1Ab (nominal p-value < 0.05). These lipids included one LPC, 12 
PCs, one PE, nine SMs and 22 TGs. All of these lipids passed the FDR threshold of 0.1 (Fig. 4a, Supplementary 
Table 2). With the exception of LPC (16:0), PC (O-22:2/22:3), PC (O-36:2), PC (O-40:5), most of the lipids were 
decreased in PT1D group (Fig. 4a). However, no clear pattern with respect to the acyl chain composition was 
observed in any specific lipid class.
Next, PLS-DA analysis between P1Ab (n = 18) and CTR (n = 18) at 3 months of age revealed increased levels 
of PCs and PEs in the P1Ab group (AUROC = 0.65; Supplementary Fig. 2b). However, no clear patterns were 
observed for the other lipid classes. Analysis of individual lipids revealed that a total of 45 lipids were altered 
between the two study groups (nominal p-value < 0.05). These lipids included two CEs, 38 PCs, four PEs, and two 
TGs. Fourty-four of these lipids passed the selected FDR threshold of 0.1 (Supplementary Table 3). The heatmap 
highlights that most of the PCs, with the exception of PC (33:0) were increased in the P1Ab group. ASCA anal-
ysis also revealed that the study group had a significant effect (p = 0.022) on the plasma lipidome profile of the 
children while the effect of gender (p = 0.60) and its interaction (p = 0.95) remained insignificant in the 3-month 
cohort.
Similarly, we analyzed the lipid concentration differences between the three study groups in the remaining 
longitudinal series at 6, 12, 18, 24 and 36 months. There was no persistent trend with respect of lipid differences 
between the groups (Fig. 4a), with the exception for SMs which were persistently low in PT1D as compared to 
P1Ab and CTR (Fig. 4b). Low levels of SMs were particularly observed at 6, 12 and 18 months (Fig. 4b). However, 
only one of the SMs, SM (d36:2), differed significantly (adjusted p < 0.1) between the PT1D and CTR at 6 and 
18 months of age (Fig. 4c). In addition, PC (33:0), TG (56:5) and TG (18:2/18:1/18:1) passed the FDR threshold 
of 0.1 at 18 months of age (Fig. 4a). Furthermore, PLS-DA analysis performed between the three study groups 
(PT1D vs. CTR, PT1D vs. P1Ab, CTR vs. P1Ab) in the remaining longitudinal series at the age of 6, 12, 18, 24 
and 36 months also showed poor classification accuracy (based on AUROC value, i.e. less than 50% classified 
accurately).
Lipidome in progression to type 1 diabetes. Next, we sought to determine the total lipid class specific 
changes in the longitudinal series of samples. Individual lipid concentrations in each lipid class were added, then 
subsequent data analysis considering each lipid class as a variable was performed. We found clear alterations in 
phospholipids, in particular SMs were significantly reduced in the PT1D group at the ages of 3 and 18 months 
when compared to the P1Ab group (Fig. 5a) and at the age of 3 month when compared to CTR (Fig. 5b). TGs 
and PCs were significantly lower in PT1D than in P1Ab at the age of 3 months (Fig. 5a,c). PEs and PCs were also 
higher in P1Ab than in CTR at the age of 3 months.
Lipidome changes before the emergence of islet autoantibodies. In order to examine whether the 
circulating lipids were associated with the appearance of islet autoantibodies, the plasma lipidome in PT1D with 
Figure 3. Regression coefficient plot from PLS-DA analysis at 3 months of age. This plot has the regression 
coefficient on the x-axis and variable importance in the projection (VIP) scores in the y-axis. A VIP score 
is a statistical estimate of importance of each variable in the PLS-DA model. In general, VIP score of >1 is 
suggest as a good candidates for the PLS-models. The regression coefficient represents the average changes in 
the response variable. The regression coefficient describe the relationship between a predictor variable (lipids) 
and the response (categorical variable CTR or PT1D). Positive sign indicates that as the predictor variable is 
positively correlated to given response variable. Here, positive and negative regression coefficients represent 
CTR and PT1D group response in the given PLS-DA model, respectively. Each lipid class is color coded. 
Abbreviations: cholesterol ester (CE), diacylglycerol (DG), lysophosphatidylcholine (LPC), phosphatidylcholine 
(PC), phosphatidylethanolamine (PE), sphingomyelin (SM) and triacylglycerol (TG).
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one Ab (n = 21) and P1Ab (n = 27) groups were compared between the samples obtained before and after the 
appearance of the first islet autoantibody, respectively. We applied the multi-level approach to exploit the paired 
data structure. Multi-level analysis revealed several differences before and after the appearance of islet autoanti-
bodies. Specifically, SMs (SM (d36:1), SM (d36:2)) and LPCs (LPC (18:0), LPC (18:2), LPC (16:0)) were higher 
while CEs (CE (20:4), CE (20:5)) were lower before seroconversion than after it in both PT1D and P1Ab (Fig. 6). 
As an exception to this pattern, LPC (20:3) appeared to be elevated after the emergence of the first autoantibody 
in P1Ab. Next, we set out to examine the individual lipid profiles by univariate analysis. The pairwise analysis 
revealed a total of 27 (two CEs, three LPCs, 11PCs, five SMs, six TGs) and 16 (two CEs, two LPCs, six PCs, four 
SMs, two TGs) lipids, respectively, being altered in both study groups (nominal p-value < 0.05, Supplementary 
Tables 4 and 5). However, only CE (20:5) passed the level of significance at the selected FDR threshold of 0.1 in 
P1Ab.
We also studied whether lipidome profiles associated with the appearance of specific islet autoantibodies. The 
plasma lipidomes were compared before and after the emergence of first insulin autoantibodies (IAA) in P1Ab 
and PT1D with one Ab. Pairwise comparisons were also performed by combining other autoantibodies as a 
group (islet cell antibodies (ICA), islet antigen 2 autoantibodies (IA-2A), and GAD autoantibodies (GADA) in the 
remaining children. The pairwise comparison revealed a total of 17 (in PT1D with first IAA), one (in PT1D with 
all others autoantibodies excluding IAA), 22 (in P1Ab with first IAA), and 11 (in P1Ab with all others autoanti-
bodies excluding IAA) lipids being altered at a nominal p-value < 0.05 before and after the appearance of specific 
Figure 4. Comparison of global lipidome between the children who progressed to T1D, who developed at 
least a single antibody but not develop T1D during the follow-up (P1Ab), and control (CTR) subjects who 
remained islet autoantibody negative during the follow-up. (a) Heat map showing 45 lipid species representative 
of lipid classes that change between PT1D, P1Ab and CTR. Differences in lipid concentrations were calculated 
by dividing mean concentration in PT1D by the mean concentrations in P1Ab and CTR. Differences were 
determined at 3, 6, 12, 18, 24 and 36 months of age between the study groups. (b) The smoothened line plot 
based on the mean SM (36:2) concentration in the three study groups. The error bar shows the standard error 
of the mean. (c) Concentrations of SM (36:2) in the three study groups at 6 months of age. # represents the 
adjusted p-values < 0.1.
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islet seroconversion (Supplementary Tables 6–9). However, none of the lipid species passed the significance at the 
FDR threshold of 0.1.
Next, we analyzed the lipid concentration differences between the specific islet (IAA vs others including IA-2, 
GADA, ICA) autoantibodies study groups in the longitudinal series at 3, 6, 12, 18, 24 and 36 months. There were 
no significant (FDR threshold of 0.1) lipid differences between the specific islet groups, with the exception for 
3 months of age, where we found a total of 23 lipids (two CEs, one PC, seven SMs, 13 TGs) being altered when 
comparing PT1D with IAA to P1Ab with IAA (Supplementary Table 10). All of these lipids passed significance 
at the FDR threshold of 0.1. SMs, TGs and PC were lower while CEs appeared to be higher at the age of 3 months 
in the PT1D group with IAA than in the P1Ab group with IAA as the first autoantibody (Supplementary Fig. 3).
Discussion
Here we showed that specific lipid changes precede islet autoimmunity and T1D. Our results revealed that the 
children who progress to T1D in the follow-up tend to have a distinct and persistently dyregulated lipid profile 
as compared to those who later progress to islet autoimmunity but not to T1D. Our observations also show that 
plasma lipids, in particular CEs, PEs, SMs and LPCs, are strongly affected by age during the early development. 
This is in agreement with earlier studies which suggest that gender, age, and body mass index have significant 
impact on the longitudinal trajectories of plasma lipids16,17. Several studies depict that serum total cholesterol 
and TGs gradually increase with age during the early development18,19, but the data specifically from infants are 
limited to phospholipids such as SMs and LPCs20. Our findings are not unexpected however, because various host 
related and environmental factors including dietary changes during the development can impact the lipid profiles 
over time21.
We found that differences in the lipidomes between the three study groups were most pronounced at the 
earliest age of 3 months. SM levels were low inPT1D as compared to the other groups. At the level of individual 
lipid species, most significant and persistent differences were observed for SM (d36:2), which differed between 
PT1D and CTR, as well as between PT1D and P1Ab at 3 months of age. Most of the other SMs also tended to be 
persistently lower in PT1D than in both CTR and P1Ab. Interestingly, the lipid-related associations with progres-
sion to T1D appear to be the strongest in the group of children who first developed positivity for IAA, which are 
also the most common first autoantibody detected in young children who later progress to T1D5 and tends to be 
associated with higher risk of progression as compared to other autoantibodies22,23.
Previous studies by us and others have also reported decreased serum SM levels in children who later pro-
gressed to T1D as well as in children with newly diagnosed T1D24,25. Sphingolipids are among the most abun-
dant choline containing phospholipids in the mammalian cells, tissues and in the circulation. Sphingolipids have 
been shown to be potent regulators of immune cell activity26. In addition, sphingolipids are crucial for plasma 
Figure 5. Total lipid concentration in each lipid class difference between the children who progressed to T1D, 
who developed at least a single antibody but did not develop T1D during the follow-up (P1Ab), and control 
(CTR) subjects who remained islet autoantibody negative during the follow-up. The comparisons were done in 
the longitudinal cohort at the ages of 3, 6, 12, 18, 24 and 36 months. Adjusted p-values < 0.1 are colored blue. 
The figure shows that SMs were downregulated in the PT1D group at the age of 3 months compared to P1Ab 
and CTR (adjusted p = 0.047). TGs were also downregulated in PT1D as compared to P1Ab (adjusted p = 0.079) 
at the age of 3 months. Furthermore, PEs and PCs were also higher in P1Ab than in CTR at the age of 3 months. 
There was no persistent trend with respect of total lipid concentration between CTR, P1Ab and PT1D in other 
the perspective series of samples.
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membrane organization and thus their concentrations might affect multiple T-cell meditated immunity27. Much 
of the T cell regulation has been demonstrated by modulating the activity of the sphingomyelinase family of 
enzymes which catalyze the breakdown of sphingomyelin into ceramide and other precursor metabolites26. Our 
results suggest that SM metabolism is disrupted among the T1D progressors from early age, already preceding the 
appearance of islet autoantibodies.
An important consideration in the search of metabolic signature of T1D progression is that blood in young 
infants is sampled in non-fasting state. In the earlier study, SMs were found to be least variable within-individuals 
in nonfasted serum samples12. This suggests that SMs may also hold promise as predictive metabolic signature 
of T1D and thus complementing genetic testing and islet autoantibody determination. Clearly more and larger 
studies in heterogeneous populations are needed to examine the complementary diagnostic value of SMs.
The total TGs and PCs were downregulated in PT1D as compared to P1Ab at 3 months of age. Consistent with 
these observations, other studies have reported perturbations in phospholipids during the early infancy among 
the T1D progressors10,24,25 as well as decreased TGs in newborn infants who later progressed to T1D24. Choline 
regulates secretion of triglyceride rich lipoprotein particles and its deficiency has been linked to lower serum 
TG concentration28. Since PCs are a major source of choline; an important epigenetic regulator in the body29, 
it is conceivable that alterations in the choline metabolism during infancy, e.g. by diet, may affect the PC levels, 
resulting in the decreased levels of TGs as well as PCs. In addition, the decreased levels of TGs may also sug-
gest increased energy demand in PT1D group as compared to P1Ab30. TGs are concentrated stores of metabolic 
energy in biological tissues31. During energy demand, TGs are hydrolyzed into free fatty acids that are taken up 
by other tissues or cells to meet the energy requirements of the organism32.
The appearance of autoantibodies was associated with down-regulation of SMs and LPCs and up-regulation 
of CEs. LPC is the main phospholipid component of oxidized low density lipoprotein (oxLDL) produced as a 
hydrolysis product of PC33. LPC regulates various intracellular signaling events triggered by the oxLDL, including 
modulation of the toll like receptor (TLR) signaling pathway and activation of macrophages which are the hall-
marks of the inflammatory and immunological processes33,34. These findings are in line with earlier observations 
that LPC dysregulation precedes the appearance of islet autoantibodies24.
Up-regulation of CEs following seroconversion to positivity for islet autoantibodies is a novel finding. Previous 
studies have provided evidence for the inflammatory effects of cholesterol accumulation35. Cholesterol accu-
mulation activated the enzyme lecithin cholesterol acyltransferase (LCAT) that modifies cholesterol to CE. The 
esterified cholesterols are subsequently taken up by the liver and discharged through bile excretion36. An efficient 
Figure 6. The multi-level (ML)-PLS-DA regression coefficient plot showing the most discriminating lipids 
between the samples obtained before the first islet autoantibody appeared and the samples after the emergence 
of the first islet autoantibody in the children who progressed to T1D (PT1D) and who developed a single 
autoantibody but not overt T1D during the follow-up (P1Ab). ML-PLS-DA can be regarded as a multivariate 
extension of a paired t-test. (a) The pairwise scatter plot shows that SM (d36:1), SM (d36:2), LPC (18:0), LPC 
(18:2) and LPC (16:0) were up-regulated while CEs (CE 20:4), CE (20:5)) were downregulated before the 
seroconversion. In addition, the plot depicts that SM (18:1/12:0) and CE (20:5) are differentially altered in 
P1Ab as compared to PT1D. (b) Univariate pairwise plot. The result from paired t-test shows that only CE 
(20:5) passed the FDR threshold of 0.1 in P1Ab after seroconversion. Abbreviations: Before seroconversion in 
P1Ab (B-P1Ab), after seroconversion in P1Ab (A-P1Ab), before seroconversion in progressors (B-PT1D), after 
seroconversion in progressors (A-PT1D).
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cholesterol esterification would improve the reverse cholesterol transport leading to a reduction in inflammatory 
lesions37. In contrast, reduced cholesterol efflux may trigger pro-inflammatory signaling pathways such as TLR 
signaling, which results in the modulation of inflammatory responses38. However, understanding of the role of 
cholesterol homeostasis with respect to islet autoimmunity is currently limited.
Taken together, our findings support earlier studies by us and others, which suggest that dysregulation of lipid 
metabolism precedes islet autoimmunity and T1D, as well as add a new knowledge that the observed changes are 
specifically and persistently associated with progression to overt disease. The distinct lipidomics profile which is 
associated with the progression to T1D appears to be most pronounced in very young children, i.e. at 3 months 
of age in our study. This suggests (1) that diversification of dietary patterns already during the development may 
mask some of the T1D-associated metabolic signatures and (2) that metabolite-based prediction of T1D may be 
most feasible in early life, already prior to the appearance of islet autoantibodies. Already in young infants, the 
lipidomics signatures of children who progress to T1D later in life are clearly different from those that do sero-
convert to a single islet autoantibody but do not progress to overt disease. Since several lipids found dysregulated 
in the PT1D group displayed an opposite pattern in the P1Ab group in relation to CTR, our findings suggest that 
PT1D and P1Ab have distinct metabotype. Since the current stratifications in studies aimed at T1D prevention 
are based on the detection of islet autoantibodies, lipidomics profiles may thus provide a valuable complementary 
tool for identifying children at highest risk of progression to T1D.
Methods
Sample and study design. The samples have been obtained from the Finnish Type 1 Diabetes Prevention 
and Prediction Study (DIPP)39. The DIPP study has screened more than 220,000 newborn infants for HLA-
conferred susceptibility to T1D in three university hospitals Turku, Tampere, and Oulu in Finland40. The subjects 
involved in the current study were chosen from the subset of DIPP children from the Tampere study center. Here, 
five longitudinal samples per child were collected between 1998 and 2012. For each child, longitudinal samples 
were obtained corresponding to either of the ages of 3, 6, 12, 18, 24, and 36 months. This cohort comprises the 
samples from 120 children: 40 progressors to T1D (PT1D), 40 who tested positive for at least one Ab in a mini-
mum of two consecutive samples but did not progress to clinical T1D during the follow-up (P1Ab), and 40 con-
trols (CTR) subjects who remained islet autoantibody negative during the follow-up until the age of 15. The three 
study groups were matched by HLA-associated diabetes risk, gender and period of birth. Selected characteristics 
of the study subjects are shown in Table 1. In total 428 non-fasting blood samples were collected for this study. 
Plasma was separated within 30 minutes after the blood collection by centrifugation at 1600 g for 20 minutes at 
room temperature. The plasma samples were stored at −80 °C until analyzed.
HLA genotyping. HLA-conferred susceptibility to T1D was analyzed using cord blood samples as 
described41. Briefly, the HLA-genotyping was performed with time-resolved fluorometry based assay for 
four alleles using lanthanide chelate labeled sequence specific oligonucleotide probes detecting DQB1*02, 
DQB1*03:01, DQB1*03:02, and DQB1*06:02/3 alleles42. The carriers of the genotype DQB1*02/DQB1*03:02 or 
DQB1*03:02/x genotypes (here x≠ DQB1*02, DQB1*03:01, DQB1*06:02, or DQB1*06:03 alleles) were catego-
rized into the T1D risk group and recruited for the DIPP follow up program.
Detection of islet autoantibodies. The participants with HLA-conferred genetic susceptibility were 
prospectively observed for the appearance of T1D associated autoantibodies (islet cell antibodies (ICA), insu-
lin autoantibodies (IAA), islet antigen 2 autoantibodies (IA-2A), and GAD autoantibodies (GADA). These 
PT1D P1Ab CTR
Gender (girls, boys) (14, 26) (14, 26) (14, 26)
Age at time of diagnosis
(mean ± SD) 4.75 ± 2.94 NA NA
Age at time of first seroconversion (mean ± SD) 1.34 ± 0.58 3.05 ± 2.50 NA
HLA risk haplotypes
High risk (DR3 - DQA1*05 - DQB1*02) /
DRB1*0401/2/4/5 - DQA1*03 - DQB1*0302, girls, boys) (4, 5) (1, 3) (2, 4)
Moderately increased risk* (7, 14) (9, 12) (5, 9)
Slightly increased risk* (2, 8) (1, 8) (1, 6)
Neutral* (2, 1) (3, 1)
Decreased risk and/or not possible to form haplotype* (0, 2) (3, 5)
Table 1. Demographic characteristics of study population. *Other than DR3 - DQA1*05 - DQB1*02)/
DRB1*0401/2/4/5 - DQA1*03 - DQB1*0302. Abbreviations: children who progressed to T1D, who developed 
at least a single antibody but not develop T1D during the follow-up (P1Ab), and control (CTR) subjects who 
remained islet autoantibody negative during the follow-up, human leukocyte antigen (HLA). The major 
genetic determinants of T1D are alleles at the HLA-DRB1 and DQB1 loci, with both susceptible and protective 
DR-DQ haplotypes present in all human populations. The carriers of the genotype DQB1*02/DQB1*03:02 
or DQB1*03:02/x genotypes (here x≠ DQB1*02, DQB1*03:01, DQB1*06:02, or DQB1*06:03 alleles) were 
categorized into the T1D risk group and recruited for the DIPP follow up program.
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autoantibodies were measured in the Diabetes Research Laboratory, University of Oulu from the plasma samples 
taken at each follow-up visit as described43. ICA were detected with the use of indirect immunofluorescence, 
whereas the other three autoantibodies were quantified with the use of specific radio binding assays44. We used 
cutoff limits for positivity of 2.5 Juvenile Diabetes Foundation (JDF) units for ICA, 3.48 relative units (RU) for 
IAA, 5.36 RU for GADA, and 0.43 RU for IA-2A. The disease sensitivity and specificity of the assay for ICA 
were 100% and 98%, respectively, in the fourth round of the international workshops on standardization of the 
ICA assay. According to the Diabetes Autoantibody Standardization Program (DASP) and Islet Autoantibody 
Standardization Program (IASP) workshop results in 2010–2015, disease sensitivities for the IAA, GADA and 
IA-2A radio binding assays were 36–62%, 64–88% and 62–72%, respectively. The corresponding disease specifi-
cities were 94–98%, 94–99% and 93–100%, respectively.
Analysis of molecular lipids. A total of 428 plasma samples were randomized and extracted 
using a modified version of the previously published Folch procedure45. 10 µL of 0.9% NaCl, 40 µL 
of CHCl3:MeOH (2:1, v/v) and 80 µL of the 3.5 µg mL−1 internal standards solution (for quality con-
trol and normalisation purposes) were added to 10 µL of each plasma sample. The standard solu-
tion contained the following compounds: 1,2-diheptadecanoyl-sn-glycero-3-phosphoethanolamine 
(PE(17:0/17:0)), N-heptadecanoyl-D-erythro-sphingosylphosphorylcholine (SM(d18:1/17:0)),N-hepta
decanoyl-D-erythro-sphingosine (Cer(d18:1/17:0)),1,2-diheptadecanoyl-sn-glycero-3-phosphocholine 
(PC(17:0/17:0)), 1-heptadecanoyl-2-hydroxy-sn-glycero-3-phosphocholine (LPC(17:0)) and 1-palmitoyl-d31-
2-oleoyl-sn-glycero-3-phosphocholine (PC(16:0/d31/18:1)), purchased from Avanti Polar Lipids, Inc. (Alabaster, 
AL, USA), and 1,2-Dimyristoyl-sn-glycero-3-phospho(choline-d13) (PC(14:0/d13)) (Sigma-Aldrich, Steinheim, 
Germany), tripalmitin-1,1,1-13C3 (TG(16:0/16:0/16:0)-13C3) and trioctanoin-1,1,1-13C3 (TG(8:0/8:0/8:0)-
13C3) (Larodan AB, Solna, Sweden). The samples were vortex mixed and incubated on ice for 30 min after which 
they were centrifuged (9400 × g, 3 min, 4 °C). 60 µL from the lower layer of each sample was then transferred 
to a glass vial with an insert and 60 µL of CHCl3:MeOH (2:1, v/v) was added to each sample. The samples were 
re-randomized and stored at −80 °C until analysis.
Calibration curves using 1-hexadecyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine 
(PC(16:0e/18:1(9Z))), 1-(1Z-octadecenyl)-2-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine 
(PC(18:0p/18:1(9Z))), 1-octadecanoyl-sn-glycero-3-phosphocholine (LPC(18:0)), 1-(1Z-octadecenyl)-
2-docosahexaenoyl-sn-glycero-3-phosphocholine (PC(18:0p/22:6)) and 1-stearoyl-2-linoleoyl-sn-glycerol 
(DG(18:0/20:4)) from Avanti Polar Lipids, Inc., 1-Palmitoyl-2-Hydroxy-sn-Glycero-3-Phosphatidylcholine 
(LPC(16:0))  f rom Larodan,  and 1,2,3-Triheptadecanoylglycerol  (TG(17:0/17:0/17:0))  and 
3β-Hydroxy-5-cholestene 3-linoleate (ChoE(18:2)) from Sigma-Aldrich were prepared prepared to the follow-
ing concentration levels: 100, 500, 1000, 1500, 2000 and 2500 ng mL−1 (in CHCl3:MeOH, 2:1, v/v) including 
1000 ng mL−1 of each internal standard.
The samples were analysed using an ultra-high-performance liquid chromatography quadrupole time-of-flight 
mass spectrometry method (UHPLC-Q-TOF-MS), which has been presented in detail previously46. Briefly, the 
UHPLC system used in this work was a 1290 Infinity system from Agilent Technologies (Santa Clara, CA, USA). 
The system was equipped with a multi sampler (maintained at 10 °C), a quaternary solvent manager and a col-
umn thermostat (maintained at 50 °C). Separations were performed on an ACQUITY UPLC® BEH C18 column 
(2.1 mm × 100 mm, particle size 1.7 µm) by Waters (Milford, USA).
The mass spectrometer coupled to the UHPLC was a 6550 iFunnel quadrupole time of flight (Q-TOF) from 
Agilent Technologies interfaced with a dual jet stream electrospray (dual ESI) ion source. All analyses were per-
formed in positive ion mode and MassHunter B.06.01 (Agilent Technologies) was used for all data acquisition.
Quality control was performed throughout the dataset by including blanks, pure standard samples, extracted 
standard samples and control plasma samples. Relative standard deviations (%RSDs) for retention times and 
peak areas for lipid standards representing each lipid class in the control plasma samples (n = 37) and in the pure 
standard samples (n = 37) were calculated. The %RSDs for the retention times were on average below 0.2% for 
both the control plasma samples and for the pure standard samples. The peak areas were normalized to the peak 
area of PC (16:0/d30/18:1) in each showing %RSDs within accepted analytical limits at averages of 13% and 14% 
for the control plasma samples and for the pure standard samples, respectively. This shows that the method is 
reliable and repeatable throughout the sample set.
Data preprocessing. MS data processing was performed using open source software MZmine 2.1847. The 
following steps were applied in the processing: (1) Crop filtering with a m/z range of 350–1700 m/z and a RT 
range of 2.5 to 21.0 min, (2) Mass detection with a noise level of 750, (3) Chromatogram builder with a min time 
span of 0.08 min, min height of 2250 and a m/z tolerance of 0.006 m/z or 10.0 ppm, (4) Chromatogram decon-
volution using the local minimum search algorithm with a 70% chromatographic threshold, 0.05 min minimum 
RT range, 5% minimum relative height, 2250 minimum absolute height, a minimum ration of peak top/edge of 1 
and a peak duration range of 0.08–5.0, (5), Isotopic peak grouper with a m/z tolerance of 5.0 ppm, RT tolerance of 
0.05 min, maximum charge of 2 and with the most intense isotope set as the representative isotope, (6) Peak filter 
with minimum 12 data points, a FWHM between 0.0 and 0.2, tailing factor between 0.45 and 2.22 and asymmetry 
factor between 0.40 and 2.50, (7) Peak list row filter keeping only peak with a minimum of 1 peak in a row, (8) Join 
aligner with a m/z tolerance of 0.006 or 10.0 ppm and a weight for of 2, a RT tolerance of 0.1 min and a weight of 1 
and with no requirement of charge state or ID and no comparison of isotope pattern, (9) Peak list row filter with a 
minimum of 53 peak in a row (=10% of the samples), (10) Duplicate peak filter with a m/z tolerance of 0.006 m/z 
or 10.0 ppm and a RT tolerance of 0.1 min, (11) Gap filling using the same RT and m/z range gap filler algorithm 
with an m/z tolerance of 0.006 m/z or 10.0 ppm, (12) Peak filter using the same parameters as under step 6, (13) 
Peak list row filter with a minimum of 265 peak in a row (=50% of the samples), (14) Identification of lipids 
www.nature.com/scientificreports/
1 0SCIenTIfIC REPORTS |  (2018) 8:10635  | DOI:10.1038/s41598-018-28907-8
using a custom database search with an m/z tolerance of 0.006 m/z or 10.0 ppm and a RT tolerance of 0.1 min, 
(15) Normalization using internal standards (PE (17:0/17:0), SM (d18:1/17:0), Cer (d18:1/17:0), LPC (17:0), TG 
(16:0/16:0/16:0)-13C3 and PC (16:0/d30/18:1)) using in-house developed R-script, (16) Data imputation of miss-
ing values were done with half of the rows minimum.
Statistical analysis. All statistical analyses were based on log2-transformed intensity data. The transformed 
data were mean centered and auto scaled prior to multivariate analysis to improve the global interpretability. The 
multivariate analysis was done using the PLS Toolbox 8.2.1 (Eigenvector Research Inc., Manson, WA, USA) in 
MATLAB 2017b (Mathworks, Inc., Natick, MA, USA). PCA of the pre-processed data was initially performed to 
highlight patterns and to emphasize variation in the dataset. ANOVA-simultaneous component analysis (ASCA) 
a multivariate extension of ANOVA analysis was performed to allow interpretation of the variation induced by 
the different factors including age, sex, case, and their interaction. Subsequently, supervised partial least square 
discriminant analysis (PLS-DA) was performed to discriminate between the samples groups (PT1D/P1Ab/CTR) 
using combination of various categorical variables (e.g. PT1D vs. CTR, PT1D vs. P1Ab) in a specific age cohort. 
The area under the receiver operating characteristic (AUROC) were calculated to evaluate the ability of discrim-
ination model to correctly classify the samples. All PLS-DA models were cross-validated by splitting the dataset 
into test sample subsets for each sub-validation experiment using random subset with ten data splits and twenty 
repeats. Furthermore, supervised multilevel partial least square discriminant analysis (ML-PLSDA), a multivar-
iate extension of paired t-test was performed to discriminate between matched paired of samples, for instance 
the before and after seroconversion samples. ML-PLSDA models were validated using double cross model vali-
dation (CMV)48 with twenty repeats. The mat lab code for ML-PLSDA is open access and available at http://www.
bdagroup.nl/.
For univariate analysis, lipid concentrations were compared using both parametric and non-parametric test 
as per requirement. Wilcoxon rank-sum test was performed for comparing the two study groups of samples (e.g. 
PT1D vs. P1Ab) in a specific age cohort assuming data violates heteroscedasticity. For comparison one sample per 
subject, closest to the age within the time window, has been used in each test. Paired t-test was performed for the 
matched groups of samples (e.g. before vs. after seroconversion). The resulting nominal p-values were corrected 
for multiple comparisons using Storey approach49 if the number of tests in a study were large (>10) or Benjamin 
and Hochberg approach50 if the number of tests were small (<10). The adjusted p-values < 0.1 (q-values) were 
considered significantly different among the group of hypotheses tested in a specific age cohort. All of the uni-
variate statistical analyses were computed in MATLAB 2017b using statistical toolbox. The fold difference was 
calculated by dividing the mean concentration of a lipid species in one group by another, for instance mean 
concentration in the PT1D by the mean concentration in P1Ab, and then illustrated by heat maps. The individual 
lipids levels were visualized as box plot using GraphPad Prism 7 (GraphPad Software, La Jolla, CA, USA).
Data availability. The lipidomics data described in this study are deposited at the MetaboLights data-
base51 with the acquisition number (MTBLS620). The associated meta-data were captured using the ISA-creator 
package available from the MetaboLights. All the data supporting the findings of this study are available from 
MetaboLights database or from the corresponding authors on reasonable request.
Ethical approval and informed consent. The ethics and research committee of the participating univer-
sity and hospital at University of Tampere, Tampere Finland, approved the study protocol. The study was con-
ducted according to the guidelines in the Declaration of Helsinki. Parent and/or legal guardian provided written 
informed consent for participation in the study.
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